🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. TD-8236

    Theravance Biopharma Ireland Umited

    Asthma

    phase 2 small molecule completed

    2 trials

  2. TD-9855

    Theravance Biopharma Ireland Umited

    Attention-Deficit/Hyperactivity Disorder

    phase 2 small molecule completed

    1 trial

  3. TD-9855

    Theravance Biopharma Ireland Umited

    Neurogenic Orthostatic Hypotension

    phase 2 small molecule completed

    1 trial

  4. TD-9855 Group 1

    Theravance Biopharma Ireland Umited

    Fibromyalgia

    phase 2 small molecule completed

    1 trial

  5. TETRACOSACTIDE , EP-104GI

    EUPRAXIA PHARMACEUTICALS INC.

    Eosinophilic esophagitis

    phase 2 small molecule active

    1 trial

  6. TEV-45478

    Teva Pharma GmbH

    Nonalcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial

  7. TEV-48574

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  8. TEV-48574

    Teva Pharma GmbH

    Asthma

    phase 2 small molecule terminated

    1 trial

  9. TEV-48574

    Teva Pharma GmbH

    Crohn Disease

    phase 2 small molecule completed

    1 trial

  10. TEV-48574 Dose Regimen A

    Teva Pharma GmbH

    Crohn Disease

    phase 2 small molecule active

    1 trial

  11. TEV-48574, Placebo IMP for sc infusion is provided as a liquid solution in the same formulation as TEV-48574, except for the absence of active protein.

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  12. TEV-53275 Dose A

    Teva Pharma GmbH

    Asthma

    phase 2 small molecule terminated

    1 trial

  13. TEV-53408

    Teva Pharma GmbH

    Celiac Disease

    phase 2 small molecule active

    1 trial

  14. TEV-53408, Placebo to match TEV-53408

    Lacuna Pharma Pty Ltd

    Celiac Disease

    phase 2 small molecule active

    1 trial

  15. TEV-56286

    Teva Pharma GmbH

    Multiple System Atrophy

    phase 2 small molecule active

    2 trials

  16. TG-873870 (Nemonoxacin)

    Biotech Pharmaceutical Co.,

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  17. TIN816, Placebo to TIN816 70mg powder for solution for injection or infusion

    Novartis Pharmaceuticals

    Acute kidney injury

    phase 2 small molecule active

    1 trial

  18. TIN816, Sterile 0.9% sodium chloride solution for infusion will be administered as placebo to participants randomized to the placebo treatment. The solution is ready to use in a 100mL infusion bag of 0.9% sodium chloride solution

    Novartis Pharmaceuticals

    Sepsis associated acute kidney injury

    phase 2 small molecule active

    1 trial

  19. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    Adult patients with refractory or relapsed follicular lymphoma

    phase 2 small molecule active

    1 trial

  20. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    High-risk B-cell acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  21. TKM-080301

    Arbutus Biopharma Corp

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  22. TKM-080301

    Arbutus Biopharma Corp

    Cancer

    phase 2 small molecule completed

    1 trial

  23. TL-895, TL-895

    Lacuna Pharma Pty Ltd

    B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  24. TL-895, TL-895, TL-895, TL-895 matching placebo, TL-895, TL-895

    Lacuna Pharma Pty Ltd

    Indolent Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources